retatrutide triple agonist gip glp-1 glucagon phase 3 2025 Synedica Retatrutide Phase 3: 28.7% Weight

"We never had the ability to lose this much weight in a healthy way before," McCoy says

When appetite is unpredictable, predictability has value

Pharmaceutical-quality formulation: 100% sterile, cosmetic-grade DERMIK product ensures consistent, reliable brightening results treatment after treatment

Some patients experience mild, short-lived constipation lasting only a few days, while others notice persistent changes in bowel habits over weeks

Complementary services like hormone optimization, IV therapy, and red light therapy may be integrated into your care, though medication safety and metabolic improvement remain the primary focus of every GLP-1 visit